Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
23.28
+0.63 (2.78%)
At close: Apr 9, 2026, 4:00 PM EDT
23.29
+0.01 (0.04%)
After-hours: Apr 9, 2026, 7:15 PM EDT
Arcus Biosciences Stock Forecast
Stock Price Forecast
The 11 analysts that cover Arcus Biosciences stock have a consensus rating of "Buy" and an average price target of $30.27, which forecasts a 30.03% increase in the stock price over the next year. The lowest target is $14 and the highest is $49.
Price Target: $30.27 (+30.03%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Arcus Biosciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 2 | 1 | 2 | 3 |
| Hold | 2 | 2 | 3 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 9 | 9 | 10 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $37 → $41 | Buy | Maintains | $37 → $41 | +76.12% | Apr 2, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $44 → $45 | Strong Buy | Maintains | $44 → $45 | +93.30% | Mar 5, 2026 |
| Leerink Partners | Leerink Partners | Buy Maintains $36 → $49 | Buy | Maintains | $36 → $49 | +110.48% | Mar 2, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +37.46% | Mar 2, 2026 |
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $30 → $23 | Buy → Hold | Downgrades | $30 → $23 | -1.20% | Feb 12, 2026 |
Financial Forecast
Revenue This Year
84.29M
from 247.00M
Decreased by -65.87%
Revenue Next Year
154.45M
from 84.29M
Increased by 83.23%
EPS This Year
-4.02
from -3.29
EPS Next Year
-3.41
from -4.02
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 148.3M | 372.2M | |||
| Avg | 84.3M | 154.5M | |||
| Low | 6.9M | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -40.0% | 341.5% | |||
| Avg | -65.9% | 83.2% | |||
| Low | -97.2% | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -3.13 | -2.14 | |||
| Avg | -4.02 | -3.41 | |||
| Low | -5.10 | -3.79 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.